2583. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
作者: Ana Maria Henao-Restrepo.;Ira M Longini.;Matthias Egger.;Natalie E Dean.;W John Edmunds.;Anton Camacho.;Miles W Carroll.;Moussa Doumbia.;Bertrand Draguez.;Sophie Duraffour.;Godwin Enwere.;Rebecca Grais.;Stephan Gunther.;Stefanie Hossmann.;Mandy Kader Kondé.;Souleymane Kone.;Eeva Kuisma.;Myron M Levine.;Sema Mandal.;Gunnstein Norheim.;Ximena Riveros.;Aboubacar Soumah.;Sven Trelle.;Andrea S Vicari.;Conall H Watson.;Sakoba Kéïta.;Marie Paule Kieny.;John-Arne Røttingen.
来源: Lancet. 2015年386卷9996期857-66页
A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, west Africa.
2587. Legionnaires' disease.
Since first identified in early 1977, bacteria of the genus Legionella are recognised as a common cause of community-acquired pneumonia and a rare cause of hospital-acquired pneumonia. Legionella bacteria multisystem manifestations mainly affect susceptible patients as a result of age, underlying debilitating conditions, or immunosuppression. Water is the major natural reservoir for Legionella, and the pathogen is found in many different natural and artificial aquatic environments such as cooling towers or water systems in buildings, including hospitals. The term given to the severe pneumonia and systemic infection caused by Legionella bacteria is Legionnaires' disease. Over time, the prevalence of legionellosis or Legionnaires' disease has risen, which might indicate a greater awareness and reporting of the disease. Advances in microbiology have led to a better understanding of the ecological niches and pathogenesis of the condition. Legionnaires' disease is not always suspected because of its non-specific symptoms, and the diagnostic tests routinely available do not offer the desired sensitivity. However, effective antibiotics are available. Disease notification systems provide the basis for initiating investigations and limiting the scale and recurrence of outbreaks. This report reviews our current understanding of this disease.
2591. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.
作者: Aparna Schweitzer.;Johannes Horn.;Rafael T Mikolajczyk.;Gérard Krause.;Jördis J Ott.
来源: Lancet. 2015年386卷10003期1546-55页
The quantification of the burden of disease attributable to hepatitis B virus (HBV) infection and the adaptation of prevention and control measures requires knowledge on its prevalence in the general population. For most countries such data are not routinely available. We estimated the national, regional, and global prevalence of chronic HBV infection.
2593. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.
作者: Elisa De Franco.;Sarah E Flanagan.;Jayne A L Houghton.;Hana Lango Allen.;Deborah J G Mackay.;I Karen Temple.;Sian Ellard.;Andrew T Hattersley.
来源: Lancet. 2015年386卷9997期957-63页
Traditional genetic testing focusses on analysis of one or a few genes according to clinical features; this approach is changing as improved sequencing methods enable simultaneous analysis of several genes. Neonatal diabetes is the presenting feature of many discrete clinical phenotypes defined by different genetic causes. Genetic subtype defines treatment, with improved glycaemic control on sulfonylurea treatment for most patients with potassium channel mutations. We investigated the effect of early, comprehensive testing of all known genetic causes of neonatal diabetes.
2594. First clinical use of a bioprosthetic total artificial heart: report of two cases.
作者: Alain Carpentier.;Christian Latrémouille.;Bernard Cholley.;David M Smadja.;Jean-Christian Roussel.;Elodie Boissier.;Jean-Noël Trochu.;Jean-Pierre Gueffet.;Michèle Treillot.;Philippe Bizouarn.;Denis Méléard.;Marie-Fazia Boughenou.;Olivier Ponzio.;Marc Grimmé.;Antoine Capel.;Piet Jansen.;Albert Hagège.;Michel Desnos.;Jean-Noël Fabiani.;Daniel Duveau.
来源: Lancet. 2015年386卷10003期1556-63页
The development of artificial hearts in patients with end-stage heart disease have been confronted with the major issues of thromboembolism or haemorrhage. Since valvular bioprostheses are associated with a low incidence of these complications, we decided to use bioprosthetic materials in the construction of a novel artificial heart (C-TAH). We report here the device characteristics and its first clinical applications in two patients with end-stage dilated cardiomyopathy. The aim of the study was to evaluate safety and feasibility of the CARMAT TAH for patients at imminent risk of death from biventricular heart failure and not eligible for transplant.
2595. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
作者: John D Grainger.;Franco Locatelli.;Thirachit Chotsampancharoen.;Elena Donyush.;Bunchoo Pongtanakul.;Patcharee Komvilaisak.;Darintr Sosothikul.;Guillermo Drelichman.;Nongnuch Sirachainan.;Susanne Holzhauer.;Vladimir Lebedev.;Richard Lemons.;Dagmar Pospisilova.;Ugo Ramenghi.;James B Bussel.;Kalpana K Bakshi.;Malini Iyengar.;Geoffrey W Chan.;Karen D Chagin.;Dickens Theodore.;Lisa M Marcello.;Christine K Bailey.
来源: Lancet. 2015年386卷10004期1649-58页
The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia.
|